The traditional HR Business Partner (HRBP) model, once the gold standard for HR delivery, is undergoing a significant transformation. Many organizations, particularly in industries like pharmaceuticals, are moving towards a more agile resource model, aiming to streamline HR operations and…
HOME > ARCHIVE
ARCHIVE
- WORLD BUSINESS NEWS IN BRIEF
March 12, 2001
- Nomura BioConference Focuses on Latest Biotechnology -1-
March 12, 2001
- BUSINESS NEWS IN BRIEF -1-
March 12, 2001
- Nomura BioConference Focuses on Latest Biotechnology -2-
March 12, 2001
- Elsevier Science Acquires MIX
March 12, 2001
- Hitachi Spins Off Instruments, Semiconductor Manufacturing Equipment Businesses
March 12, 2001
- Maruishi: Sevofrane Pushes Sales to \32 Bil., Up 6.4%
March 12, 2001
- Mitsubishi Ties Up with TeraRecon in 3D Graphics Business
March 12, 2001
- Approval of 8 New Drugs Including Radicut, Fiblast Spray Granted
March 12, 2001
- DIAGNOSTIC NEWS IN BRIEF
March 12, 2001
- More Strict with Hospitals in Illegal Cases: New Medical Service Law
March 12, 2001
- OTC NEWS IN BRIEF
March 12, 2001
- Nicorette Reexamined, 2 New Orphan Drugs Designated
March 12, 2001
- Sankyo Aims at \1 Trillion Sales in FY2010: President Takato
March 12, 2001
- Q&A Booklet on New PMS for 6 Months after Launching Issued
March 12, 2001
- MTP Ties Up with Sumitomo, MedGene Regarding HGF
March 12, 2001
- REGULATORY NEWS IN BRIEF
March 12, 2001
- Hokuriku: Hokunalin Tape, Ganaton Boost Sales, Operating Profits
March 12, 2001
- Taisho Signs Anti-Asthma Drug License Agreement with EpiGenesis
March 12, 2001
- JMARI to Conduct Survey to Propose New Medical Fee Payment Method
March 12, 2001
ページ
Japan relies almost entirely on China for the APIs of β-lactam antibiotics. These drugs are essential for treating infectious diseases…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…